A Phase 2 interventional study of Plecanatide and Matching placebo in Irritable Bowel Syndrome With Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 35 sites in United States. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 2, and was the 10th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2018.
This study's enrollment of 218 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 in phase 2, and was the 20th registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if plecanatide can improve bowel function and relieve symptoms of irritable bowel syndrome with constipation (IBS-C) in children and adolescents aged 6 to \<18 years. The main questions it aims to answer are:
Participants will:
This study is a randomized, double-blind, placebo-controlled, dose-ranging clinical trial designed to evaluate the safety, efficacy, and pharmacokinetics of plecanatide in pediatric patients aged 6 to \<18 years with irritable bowel syndrome with constipation (IBS-C). IBS-C is a condition that causes abdominal pain and infrequent, hard bowel movements.
The study includes two age cohorts:
Group A: 6 to 11 years Group B: 12 to \<18 years
Participants are randomly assigned to receive one of four plecanatide doses (0.5 mg, 1.0 mg, 2.0 mg, or 3.0 mg) or placebo. All treatments were taken orally once daily for 4 weeks following a 28-day screening/baseline period. After treatment, participants were followed for 2 weeks.
The primary objective is to determine whether plecanatide increases the number of spontaneous bowel movements (SBMs) compared to placebo.
Secondary objectives include:
Time to first bowel movement after starting treatment Changes in stool consistency Changes in abdominal pain and discomfort Overall safety and tolerability of plecanatide
Safety assessments include monitoring adverse events, laboratory tests, and treatment compliance. Participants recorded daily bowel habits and symptoms in an electronic diary and attended scheduled clinic visits for evaluations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient will be eligible for study participation if he or she meets all of the following criteria:
For at least 2 months before diagnosis the patient has had:
Abdominal pain at least 4 days per month associated with one or more of the following:
3. Patient's parent/guardian/LAR is able to voluntarily provide written, signed, and dated consent and patient is able to voluntarily provide assent as per IRB guidance; 4. Patient and patient's parent/guardian/LAR demonstrates an understanding, ability, and willingness to fully comply with protocol requirements and study procedures (e.g., acceptance of venipuncture, acceptance of urine drug screen for opiates, visit schedule, complete daily electronic diary reporting).
EXCLUSION CRITERIA
A patient will be excluded from the study if he or she meets any of the following criteria:
Females age 12 to \< 18 or females age 6 to 11 of (defined as post menarche) who does not agree to practice one of the following medically acceptable methods of throughout the study;
The patient has a sibling that is currently participating or has participated in another Synergy study.
Exclusion Criteria Based on Baseline Diary Entries
Patient reports worst abdominal pain intensity (WAPI) scores in the 2-week baseline diary that meet either of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
Drug: Plecanatide
Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old
Drug: Plecanatide
Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to 18 Years of Age
Drug: Plecanatide
Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to \< 18 years old
Drug: Plecanatide
Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old
Drug: Matching placebo
Plecanatide 1.0 mg Taken orally daily for 4 weeks Group B: ≥ 12 to \< 18 Years of Age
Drug: Plecanatide
Matching placebo Taken orally daily for 4 weeks Group B: 12 to \< 18 years old
Drug: Matching placebo
Taken orally daily for 4 weeks
Also known as: Trulance
Taken orally daily for 4 weeks
Also known as: No other names
Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups
Weekly SBM rate computed for each week
Time frame: Baseline to Week 4
Change From Baseline in Frequency of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..
Weekly frequency was calculated as the number of abdominal pain episodes and abdominal discomfort episodes per week, based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline assessment period. Values shown are mean change from baseline (SD).
Time frame: Baseline to Week 4
Change From Baseline in Severity of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..
Severity of abdominal pain and abdominal discomfort was recorded daily using an electronic diary on a 0-10 numeric rating scale (0 = no pain/discomfort; 10 = worst possible). Weekly averages were calculated; baseline was the average score during the 2-week baseline period. Values shown are mean change from baseline.
Time frame: Baseline to Week 4
Change From Baseline in Frequency of Complete Spontaneous Bowel Movements (CSBM)
Weekly frequency of complete spontaneous bowel movements (CSBMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD) at end of 4 weeks of study.
Time frame: Baseline to Week 6
Change From Baseline in Frequency of Bowel Movements (BM)
Weekly frequency of bowel movements (BMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD).
Time frame: Baseline to Week 4
Time to First Bowl Movement (in Days)
This outcome was analyzed as a time-to-event variable (time to first complete spontaneous bowel movement), and confidence intervals were estimated using Kaplan-Meier methods.
Time frame: Day 1 to first BM during Treatment Period
Change From Baseline in Stool Consistency (Based on Bristol Stool Form Scale, BSFS or Modified Bristol Stool Form Scale for Children, mBSFS-C)
Weekly stool consistency scores based on BSFS (≥12 years) or mBSFS-C (6-11 years). BSFS Scale is a 7 point scale, from Type 1 (Hard to pass) to Type 7 (entirely liquid). mBSFS-C is a 5 point scale, from Type 1 (hard to pass) to Type 5 (watery, no solid pieces).
Time frame: Baseline to Week 4
Use of Rescue Medication
Number of rescue medication tablets (Dulcolax® 5 mg) used during the 4-week treatment period. Subjects were instructed to use rescue medication only if ≥72 hours had passed since last bowel movement.
Time frame: Baseline to Week 4
Change From Baseline in Frequency of Fecal Incontinence
Weekly fecal incontinence episodes recorded in daily diary.
Time frame: Baseline to Week 4
Change From Baseline in Severity of Defecation Pain
Severity of abdominal pain scored daily on a 0-10 numeric rating scale (0 = no pain, 10 = worst possible pain). Weekly averages were calculated from daily scores.
Time frame: Baseline to Week 4
Change From Baseline in Frequency of Pain With Defecation
Pain with defecation was recorded in daily diaries as the number of episodes per week. Results represent the mean change from baseline in weekly frequency.
Time frame: Baseline to Week 4
Change From Baseline in Frequency of Large Diameter Stools
Weekly frequency of large diameter stools recorded in daily diary.
Time frame: Baseline to Week 4
| Milestone | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Started | 30 | 29 | 29 | 34 | 32 | 32 | 32 |
| Completed | 29 | 26 | 28 | 34 | 27 | 31 | 29 |
| Not completed | 1 | 3 | 1 | 0 | 5 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Participant moved and was unable to complete study | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Non-compliance with ediary | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Weekly SBM rate computed for each week
| Number of SBMs per week | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups | 0.6 ± 2.24 | 0.8 ± 1.75 | 0.6 ± 1.53 | 1.0 ± 2.08 | 1.1 ± 2.20 | .70 ± 2.45 | -0.2 ± 1.95 |
Weekly frequency was calculated as the number of abdominal pain episodes and abdominal discomfort episodes per week, based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline assessment period. Values shown are mean change from baseline (SD).
| Episodes per week | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | ExperimentaL: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching placebo - Group B |
|---|---|---|---|---|---|---|---|
| Frequency of Abdominal Pain | -2.7 ± 2.27 | -2.2 ± 2.38 | -1.4 ± 2.47 | -1.3 ± 1.49 | -1.6 ± 2.34 | -1.4 ± 2.26 | -1.6 ± 2.56 |
| Frequency of Abdominal Discomfort | -2.5 ± 2.18 | -2.1 ± 2.35 | -1.3 ± 2.44 | -0.9 ± 1.59 | -1.5 ± 2.22 | -1.1 ± 2.03 | -1.3 ± 2.43 |
Severity of abdominal pain and abdominal discomfort was recorded daily using an electronic diary on a 0-10 numeric rating scale (0 = no pain/discomfort; 10 = worst possible). Weekly averages were calculated; baseline was the average score during the 2-week baseline period. Values shown are mean change from baseline.
| Severity score (0-10 scale) | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | ExperimentaL: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching placebo - Group B |
|---|---|---|---|---|---|---|---|
| Severity of Abdominal Pain | -3.3 ± 3.07 | -2.3 ± 2.72 | -2.3 ± 2.33 | -2.2 ± 2.37 | -2.8 ± 2.19 | -2.56 ± 2.27 | -2 ± 2.36 |
| Severity of Abdominal Discomfort | -3.4 ± 2.97 | -2.4 ± 2.83 | -2.40 ± 2.51 | -1.9 ± 2.58 | -3.0 ± 2.23 | -2.5 ± 2.36 | -2.0 ± 2.46 |
Weekly frequency of complete spontaneous bowel movements (CSBMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD) at end of 4 weeks of study.
| Change in Number of CSBMs per week | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Frequency of Complete Spontaneous Bowel Movements (CSBM) | 0.7 ± 1.73 | 0.2 ± 0.75 | 0.2 ± 0.91 | 0.4 ± 0.85 | 0.1 ± 1.07 | 0.7 ± 1.79 | -0.1 ± 0.47 |
Weekly frequency of bowel movements (BMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD).
| Number of BMs per week | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Frequency of Bowel Movements (BM) | 0.5 ± 2.24 | 0.8 ± 1.7 | 0.6 ± 1.52 | 0.8 ± 2.06 | 1.0 ± 2.23 | 0.8 ± 2.263 | 0 ± 2.05 |
This outcome was analyzed as a time-to-event variable (time to first complete spontaneous bowel movement), and confidence intervals were estimated using Kaplan-Meier methods.
| Days | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Time to First Bowl Movement (in Days) | 4.1 (1.13 to 11.43) | 2.58 (1.56 to 6.21) | 5.35 (2.35 to NA) | 1.68 (0.99 to 5.23) | 2.05 (0.86 to 6.25) | 2.57 (0.89 to 8.15) | 2.69 (1.35 to 5.28) |
Weekly stool consistency scores based on BSFS (≥12 years) or mBSFS-C (6-11 years). BSFS Scale is a 7 point scale, from Type 1 (Hard to pass) to Type 7 (entirely liquid). mBSFS-C is a 5 point scale, from Type 1 (hard to pass) to Type 5 (watery, no solid pieces).
| Score (BSFS or mBSFS-C) | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Stool Consistency (Based on Bristol Stool Form Scale, BSFS or Modified Bristol Stool Form Scale for Children, mBSFS-C) | 1.2 ± 1.12 | 0.8 ± 1.18 | 1.2 ± 0.72 | 1.1 ± 1.24 | 1.4 ± 1.5 | 1.9 ± 1.35 | 0.7 ± 0.96 |
Number of rescue medication tablets (Dulcolax® 5 mg) used during the 4-week treatment period. Subjects were instructed to use rescue medication only if ≥72 hours had passed since last bowel movement.
| Number of Tablets | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Use of Rescue Medication | 1.3 ± 3.6 | 0.7 ± 3.22 | 0.4 ± 1.18 | 2.4 ± 8.73 | 0.2 ± 0.59 | 1.6 ± 5.02 | 2.4 ± 6.68 |
Weekly fecal incontinence episodes recorded in daily diary.
| Number of episodes per week | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Frequency of Fecal Incontinence | 0.3 ± 2.10 | 1.9 ± 4.36 | 1.1 ± 3.04 | 0.9 ± 2.58 | 2.3 ± 5.33 | 1.0 ± 2.73 | 1.3 ± 3.29 |
Severity of abdominal pain scored daily on a 0-10 numeric rating scale (0 = no pain, 10 = worst possible pain). Weekly averages were calculated from daily scores.
| Severity Score 0-10 scale | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Severity of Defecation Pain | -2.4 ± 3.13 | -2.6 ± 3.16 | -2.6 ± 3.62 | -2.3 ± 2.98 | -2.5 ± 2.17 | -1.8 ± 2.7 | -1.6 ± 2.83 |
Pain with defecation was recorded in daily diaries as the number of episodes per week. Results represent the mean change from baseline in weekly frequency.
| Change in Episodes per week | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Frequency of Pain With Defecation | -0.3 ± 2.64 | -0.8 ± 2.97 | -0.3 ± 2.91 | 0.4 ± 2.33 | -0.5 ± 2.29 | -0.8 ± 2.55 | -0.7 ± 2.58 |
Weekly frequency of large diameter stools recorded in daily diary.
| Number of episodes per week | Experimental: 0.5 mg plecanatide | Experimental: 1.0 mg plecanatide - Group A | Matching placebo - Group A | Experimental: 1.0 mg plecanatide - Group B | Experimental: 2.0 mg plecanatide | Experimental: 3.0 mg plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Frequency of Large Diameter Stools | 0 ± .28 | 0 ± 0.48 | 0.1 ± 0.57 | 0.0 ± 0.61 | -0.1 ± 0.49 | 0.0 ± 0.40 | 0.1 ± 0.67 |
Collected over From consent signature until end of study participation, up to 10 weeks. This includes screening, 4-week treatment, and 2-week follow-up periods.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: 0.5 mg Plecanatide | 0/30 (0%) | 0/30 (0%) | 2/30 (6.7%) |
| Experimental: 1.0 mg Plecanatide - Group A | 0/29 (0%) | 0/29 (0%) | 5/29 (17.2%) |
| Matching Placebo - Group A | 0/29 (0%) | 0/29 (0%) | 1/29 (3.4%) |
| Experimental: 1.0 mg Plecanatide - Group B | 0/34 (0%) | 0/34 (0%) | 7/34 (20.6%) |
| Experimental: 2.0 mg Plecanatide | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Experimental: 3.0 mg Plecanatide | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Matching Placebo - Group B | 0/32 (0%) | 0/32 (0%) | 2/32 (6.3%) |
| Event | Experimental: 0.5 mg Plecanatide | Experimental: 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | Experimental: 1.0 mg Plecanatide - Group B | Experimental: 2.0 mg Plecanatide | Experimental: 3.0 mg Plecanatide | Matching Placebo - Group B |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/30 | 2/29 | 0/29 | 1/34 | 1/32 | 1/32 | 1/32 |
| Abdominal PainGastrointestinal disorders | 0/30 | 0/29 | 0/29 | 2/34 | 1/32 | 0/32 | 0/32 |
| PyrexiaGeneral disorders | 0/30 | 1/29 | 0/29 | 0/34 | 0/32 | 0/32 | 0/32 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/30 | 1/29 | 0/29 | 0/34 | 0/32 | 0/32 | 0/32 |
| FlatulenceGastrointestinal disorders | 0/30 | 0/29 | 1/29 | 1/34 | 1/32 | 1/32 | 0/32 |
| DiarrheaGastrointestinal disorders | 1/30 | 1/29 | 1/29 | 1/34 | 1/32 | 0/32 | 0/32 |
| RashSkin and subcutaneous tissue disorders | 1/30 | 0/29 | 0/29 | 0/34 | 0/32 | 0/32 | 0/32 |
| VomitingGastrointestinal disorders | 0/30 | 0/29 | 0/29 | 0/34 | 1/32 | 0/32 | 0/32 |
| HypothyroidismEndocrine disorders | 0/30 | 0/29 | 0/29 | 0/34 | 0/32 | 1/32 | 0/32 |
| COVID-19Infections and infestations | 0/30 | 0/29 | 0/29 | 0/34 | 0/32 | 1/32 | 0/32 |
Full Analysis Set (FAS) includes all randomized and treated subjects who have the baseline assessment and at least one post randomization assessment of the primary efficacy measure of weekly SBM frequency.
| Age, Customized(Participants) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| Age Group — Group A: Age 6 to 11 | 30 | 29 | 29 | 0 | 0 | 0 | 0 | 88 |
| Age Group — Group B: Age 12 to <18 | 0 | 0 | 0 | 34 | 32 | 32 | 32 | 130 |
| Sex: Female, Male(Participants) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 16 | 15 | 15 | 20 | 20 | 20 | 20 | 126 |
| Male | 14 | 14 | 14 | 14 | 12 | 12 | 12 | 92 |
| Race (NIH/OMB)(Participants) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 4 | 2 | 5 | 6 | 6 | 2 | 2 | 27 |
| White | 26 | 27 | 22 | 28 | 25 | 30 | 30 | 188 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 23 | 27 | 23 | 25 | 24 | 27 | 28 | 177 |
| Not Hispanic or Latino | 7 | 2 | 6 | 9 | 8 | 5 | 4 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 30 | 29 | 29 | 34 | 32 | 32 | 32 | 218 |
| Height at Screening (m)(meters) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 1.37 ± 0.136 | 1.36 ± 0.135 | 1.38 ± 0.131 | 1.63 ± 0.091 | 1.60 ± 0.097 | 1.58 ± 0.079 | 1.63 ± 0.086 | 1.51 ± 0.159 |
| Weight at Screening(kilograms) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 37.53 ± 11.980 | 39.55 ± 15.118 | 38.79 ± 17.070 | 66.35 ± 22.402 | 60.72 ± 14.050 | 58.21 ± 16.223 | 63.60 ± 16.62 | 52.73 ± 20.231 |
| BMI at Screening(kg/m^2) | 0.5 mg Plecanatide | 1.0 mg Plecanatide - Group A | Matching Placebo - Group A | 1.0 mg Plecanatide - Group B | 2.0 mg Plecanatide | 3.0 mg Plecanatide | Matching Placebo - Group B | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 19.82 ± 4.961 | 20.87 ± 6.678 | 19.64 ± 5.590 | 24.85 ± 7.129 | 23.66 ± 4.460 | 23.26 ± 6.230 | 23.74 ± 4.867 | 22.385 ± 6.035 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2018 to primary completion in Nov 2024, 76 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 24 industry-sponsored phase 2 interventional studies under Constipation, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 76 months is above that.
Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →